Biosig Technologies Inc

BioSig Technologies, Inc. is a medical technology company, which engages in the development of a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of electrocardiographic and intra-cardiac signals. Its product PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intra-cardiac signals for patients undergoing electrophysiology procedures. The company was founded by Kenneth L. Londoner on February 24, 2009 and is headquartered in Westport. CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

You've probably heard by now of Gilead's promising COVID-19 drug, remdesivir. But there's another experimental drug that just might capture investors' attention in the near future.

Could This Under-the-Radar Biotech Piggyback on Gilead's Remdesivir Success?

Westport, CT, May  01, 2020  (GLOBE NEWSWIRE) --  BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it plans to resume its clinical activities following the gradual return to elective procedures across the nation.

BioSig Resumes Clinical Activities with PURE EP System

In February, when the first coronavirus-infected cruise goers came home to the U.S., the biodefense lab in Galveston pulled from its freezer one of five antiviral drug candidates developed by Celgene spinoff Trek Therapeutics.

BioSig's CEO On Why The Medtech Company Bought An Antiviral Candidate To Fight Coronavirus: 'This Drug Is Really Far Along'

BioSig Technology (NASDAQ: BSGM) shares are trading higher on Friday after the company's subsidiary VirtalClear submitted an investigational new drug application to the FDA for a Phase 2 clinical trial of Merimepodib.

Why BioSig Technology's Stock Is Trading Higher Friday

Westport, CT, April  24, 2020  (GLOBE NEWSWIRE) --  BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) today announced that its subsidiary ViralClear Pharmaceuticals, Inc. submitted an Investigational New Drug (IND) Application to the Food and Drug Administration (FDA) for its Phase II clinical trial with Merimepodib as a treatment for COVID-19.

BioSig Subsidiary ViralClear Submits Investigational New Drug Application to the FDA for Phase II Clinical Trials for Merimepodib, an Orally Administered Treatment for Patients with COVID-19

Westport, CT, April  23, 2020  (GLOBE NEWSWIRE) --  BioSig Technologies, Inc. (Nasdaq:  BSGM ) today announced that an article titled, “ The IMPDH inhibitor merimepodib has similar antiviral activity against SARS-CoV-2 replication in vitro to the adenosine analogue remdesivir” was accepted by F1000 Research, an  online peer-reviewed life sciences journal publishing program in biology and medicine.

ViralClear Publishes Comparative In Vitro Data on Merimepodib and Remdesivir Activity Against the COVID-19 Novel Coronavirus in F1000 Research

Westport, CT, April  21, 2020  (GLOBE NEWSWIRE) --  BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) today appointed Mr. Anthony (‘Tony’) Zook to the Board of Directors of its majority-owned subsidiary ViralClear Pharmaceuticals, Inc.  

Tony Zook Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc.

Westport, CT, April  21, 2020  (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) today announced that on April 16, 2020 its subsidiary ViralClear Pharmaceuticals, Inc. submitted an application for Vicromax(tm_ (merimepodib, or MMPD) through the FDA’s Coronavirus Treatment Acceleration Program (CTAP) to administer the drug to hospitalized patients with COVID-19.

BioSig Subsidiary ViralClear Submits Application for Vicromax™ Through FDA’s Coronavirus Treatment Acceleration Program (CTAP) to Seek Acceleration of its Planned Clinical Trials

Westport, CT, April  17, 2020  (GLOBE NEWSWIRE) --  BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology Company commercializing a proprietary biomedical signal processing platform, today announced that the Company has issued an April 2020 Letter to Shareholders providing highlights on the Company’s recent developments and updates.

BioSig Issues April 2020 Shareholder Update Letter

Westport, CT, April  16, 2020  (GLOBE NEWSWIRE) --  BioSig Technologies, Inc. (NASDAQ: BSGM) today announced that its subsidiary ViralClear Pharmaceuticals, Inc. updated its clinical development program for Vicromax™ (merimepodib, or MMPD) as a treatment for COVID-19.

Mayo Clinic preparing to Commence Phase II FDA clinical trial for the treatment of COVID-19 with Vicromax™

Westport, CT, April  09, 2020  (GLOBE NEWSWIRE) --  BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform, today announced  that an article titled “The IMPDH inhibitor merimepodib suppresses SARS-COV-2 replications” to bioRxiv, an online archive and distribution service for reprints in the life sciences. This manuscript is  authored by Natalya Bukeryeva, Emily Mantlo, Rachel Sattler, Chen Huang, Slododan Paessler of the UTMB Galveston National Laboratory and Dr.  Jerome Zeldis of ViralClear.

Positive Data Generated by Biosig Subsidiary ViralClear on Covid-19 Coronavirus Published in bioRxiv

BioSig Technologies, Inc. (BSGM) CEO Ken Londoner on Development Updates Regarding Vicromax Conference Call (Transcript)

Westport, CT, April  03, 2020  (GLOBE NEWSWIRE) --  BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform, today announced that it intends to provide a public business update via teleconference regarding its recently acquired anti-viral pharmaceutical candidate, Vicromax(tm). The briefing is being held on Tuesday, April 7, 2020 at 11am ET.

BioSig to Host Telebriefing on Development Updates Regarding Vicromax(tm), a Novel Broad-Spectrum Anti-Viral Candidate That May Treat COVID-19

Former Chief Medical Officer of Celgene to lead development of Vicromax(tm), a novel broad-spectrum anti-viral agent that may treat COVID-19 Former Chief Medical Officer of Celgene to lead development of Vicromax(tm), a novel broad-spectrum anti-viral agent that may treat COVID-19

Jerome Zeldis, M.D., Ph.D, Appointed as Executive Chair of ViralClear Pharmaceuticals, Inc.

Novel pharmaceutical Vicromax(tm)* has already undergone extensive animal testing and human clinical experience in other indications Novel pharmaceutical Vicromax(tm)* has already undergone extensive animal testing and human clinical experience in other indications

BioSig subsidiary NeuroClear acquires license for a broad-spectrum anti-viral agent that may treat COVID-19. Laboratory results demonstrate high level of activity against COVID-19 in cell culture

One of the nation’s leading cardiologists and Medical Director of UHealth Cardiology to advise on clinical practices One of the nation’s leading cardiologists and Medical Director of UHealth Cardiology to advise on clinical practices

Florida Cardiologist Zachariah P. Zachariah, M.D.

New research project to focus on development of technological solutions for sympathetic nervous system disease New research project to focus on development of technological solutions for sympathetic nervous system disease

BioSig Appoints John W. Osborn, Ph.D.

Westport, CT, Feb.  26, 2020  (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company will be presenting at the Cowen & Co. 40th Annual Health Care Conference. The Conference is being held on March 2-4, 2020 at the Boston Marriott Copley Place in Boston, Massachusetts.

BioSig to Present at the Cowen & Co. 40th Annual Health Care

Westport, CT, Feb.  21, 2020  (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it has agreed to sell 2,500,000 shares of its common stock, $0.001 par value per share, in a “best efforts” underwritten offering for gross proceeds of $10 million. The offering is expected to close on February 25, 2020, subject to customary closing conditions.

BioSig Announces $10 Million Public Offering of Common Stock

WESTPORT, Feb.  19, 2020  (GLOBE NEWSWIRE) --  BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company successfully completed 100 patient cases with its PURE EP(tm) System.

BioSig Completes 100th Patient Case with PURE EP(TM) System

PURE EP(tm) System to be highlighted in a Spotlight session by Andrea Natale, M.D., Texas Cardiac Arrhythmia Institute PURE EP(tm) System to be highlighted in a Spotlight session by Andrea Natale, M.D., Texas Cardiac Arrhythmia Institute

BioSig to Present at the 25th Annual International AF Symposium

Second institution to begin patient enrollments with PURE EP(TM) System Second institution to begin patient enrollments with PURE EP(TM) System

BioSig to Commence Patient Cases at Mayo Clinic

Westport, CT, Jan.  14, 2020  (GLOBE NEWSWIRE) --  BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the US Patent Office allowed a fifth utility patent covering its PURE EPTM System. The recently allowed patent application number 16/195,562 entitled "APPARATUS AND METHODS FOR REMOVING A LARGE-SIGNAL VOLTAGE OFFSET FROM A BIOMEDICAL SIGNAL" was filed on November 19, 2018. The claims address methods for removing a voltage offset from a biomedical signal, such as low amplitude cardiac signals during an ablation procedure in the presence of noise. 

BioSig Awarded Additional US Patent Claims for its PURE EP(TM) System

Westport, CT, Dec.  03, 2019  (GLOBE NEWSWIRE) --      ·The Company partners with Reified Capital, a provider of advanced artificial intelligence-focused technical advisory services to the private sector

BioSig Technologies Announces New Collaboration on Development of Artificial Intelligence Solutions in Healthcare

BioSig Technologies (BSGM) signs agreement with Mayo Foundation for improving arrhythmia treatment along with covering therapies for autonomic nervous system disease.

News for Biosig Technologies Inc Stock (BSGM)